Credit Suisse Downgrades Pharmacyclics (PCYC) to Neutral

Wedbush Downgrades Pharmacyclics (PCYC) to Neutral; Potential Takeover Mostly Priced In

March 3, 2015 7:13 AM EST

Wedbush downgraded Pharmacyclics (NASDAQ: PCYC) from Outperform to Neutral with a price target of $234.00 (from $225.00) on the expectation that an acquisition of PCYC is likely to occur in the near future.

Analyst David Nierengarten commented, "Third-party reports indicated last week that... More

Goldman Sachs Downgrades Pharmacyclics (PCYC) to Neutral

February 27, 2015 6:32 AM EST

Goldman Sachs downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Neutral.

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $217.82 yesterday.

... More

Pharmacyclics (PCYC) PT Raised to $240 at Baird; Sees 'Fire Behind This Smoke'

February 26, 2015 8:59 AM EST

Baird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Pharmacyclics (NASDAQ: PCYC) to $240.00 (from $200.00) following takeover reports.

Skorney commented, "We really struggled over whether or not to downgrade following the share price surge off of yesterday's Bloomberg article. Despite our initial temptation to take... More

Pharmacyclics (PCYC) Worth Up to $274/Share in Takeout - Nomura

February 26, 2015 8:30 AM EST

Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and $196 price target on Pharmacyclics (NASDAQ: PCYC) following reports yesterday that Novartis and Johnson & Johnson are interested in acquiring Pharmacyclics at a potential valuation of $17bn-$18bn.

Somaiya commented, "Based on our DCF and... More

WallachBeth Capital Downgrades Pharmacyclics (PCYC) to Hold

February 26, 2015 8:07 AM EST

WallachBeth Capital downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Hold.

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $220.22 yesterday.

... More

Pharmacyclics (PCYC) Could Fetch $19B - FT

February 25, 2015 2:50 PM EST

Pharmacyclics (NASDAQ: PCYC) previously rumored sale to Johnson & Johnson (NYSE: JNJ) could fetch $19 billion, according to reports in the Financial Times.

... More

Deutsche Bank Downgrades Pharmacyclics (PCYC) to Hold

February 25, 2015 2:08 PM EST

Deutsche Bank downgraded Pharmacyclics (NASDAQ: PCYC) from Buy to Hold with a price target of $235 (from $205). The change follows rumors about a potential acquisition. Analyst Robyn Karnauskas sees takeout valuation at $226-256 per share.

"Every addl $1B in... More

Bernstein Skeptical of Pharmacyclics (PCYC) Takeover Report - Feuerstein

February 25, 2015 1:24 PM EST

TheStreet's biotech watcher Adam Feuerstein notes that Bernstein trading desk is skeptical of today's takeover rumors on Pharmacyclics (NASDAQ: PCYC).

Bernstein trading desk reaction to $PCYC takeout rumor. Skeptical. pic.twitter.com/SxiF83x0mh

Adam Feuerstein (@adamfeuerstein) February 25, 2015... More

Pharmacyclics (PCYC) Said to Weigh Possible Sale (JNJ) (NVS)

February 25, 2015 12:42 PM EST

(Updated - February 25, 2015 12:54 PM EST)

Pharmacyclics (Nasdaq: PCYC) said to weigh sale, according to Bloomberg.

UPDATE - Market speculation has Pharmacyclics getting $17 to $18 billion in a buyout, which is 13 to 20 percent above recent trading levels.

Potential suitors... More